Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 8/20 | 1.00 |
| ▸ | CA9 | Q16790 | 9/20 | 0.71 |
| ▸ | CA12 | O43570 | 7/20 | 0.71 |
| ▸ | CA1 | P00915 | 7/20 | 0.71 |
| ▸ | CA7 | P43166 | 7/20 | 0.71 |
| ▸ | CA13 | Q8N1Q1 | 7/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.71 |
| ▸ | CASP1 | P29466 | 3/20 | 0.71 |
| ▸ | CASP7 | P55210 | 3/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169352 | 1.00 | MCL1 (1.00) | MCL1CA9CA12CA1CA7 | |
| Fraxetin SCHEMBL43472 | 0.83 | CA9 (1.00) | MCL1CA9CA12CA1CA7 | |
| Fraxetin SCHEMBL30010613 | 0.83 | CA9 (1.00) | MCL1CA9CA12CA1CA7 | |
| SCHEMBL3192217 | 0.81 | MCL1 (0.69) | MCL1CA9CA12CA1CA7 | |
| SCHEMBL29396102 | 0.80 | CA9 (1.00) | MCL1CA9CA12CA1CA7 | |
| SCHEMBL3190311 | 0.80 | CA9 (1.00) | MCL1CA9CA12CA1CA7 | |
| SCHEMBL3362753 | 0.80 | CA9 (0.70) | MCL1CA9CA12CA1CA7 | |
| SCHEMBL4181037 | 0.80 | MCL1 (0.67) | MCL1CA9CA12CA1CA7 | |
| SCHEMBL16283617 | 0.79 | CA9 (1.00) | MCL1CA9CA12CA1CA7 | |
| Methoxymethane SCHEMBL2253445 | 0.79 | CA9 (0.97) | MCL1CA9CA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250113823-A1 | Arthropod Control Compositions | FIRMENICH SA (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4444095-A1 | ARTHROPOD CONTROL COMPOSITIONS | Firmenich SA (CH) | 2024-10-16 | — | — | EP | disclosed |
| CN-114874410-B | Photoinitiated self-repairing shape memory polyurethane and preparation method and application thereof | 广东工业大学 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023139053-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2023-07-27 | — | — | WO | disclosed |
| CN-114874410-A | Photo-induced self-repairing shape memory polyurethane and preparation method and application thereof | 广东工业大学 | 2022-08-09 | — | — | CN | disclosed |
| CN-102688231-B | Drug combination | JILIN SHENGYA MEDICAL TECHNOLOGY CO LTD | 2014-05-21 | — | — | CN | disclosed |
| CN-102688231-B | Drug combination | JILIN SHENGYA MEDICAL TECHNOLOGY CO LTD | 2014-05-21 | — | — | CN | disclosed |
| CN-102688231-A | Drug combination | JILIN SHENGYA MEDICAL TECHNOLOGY CO LTD | 2012-09-26 | — | — | CN | disclosed |
| CN-102688231-A | Drug combination | JILIN SHENGYA MEDICAL TECHNOLOGY CO LTD | 2012-09-26 | — | — | CN | disclosed |
| US-20100168225-A1 | Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors | JEAN FRANCOIS | 2010-07-01 | — | — | US | disclosed |
| US-20100168225-A1 | Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors | JEAN FRANCOIS | 2010-07-01 | — | — | US | disclosed |
| WO-2008128344-A1 | SMALL-MOLECULE HEPATITIS C VIRUS (HCV) NS3/4A SERINE PROTEASE INHIBITORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168225-A1 | Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors | SRR, HAVCR2, CBR3 | MCL1 4302/4885CA9 1119/4885CA12 1052/4885 |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | MCL1 3353/4885CA9 2021/4885CA12 4180/4885 |
| US-20250113823-A1 | Arthropod Control Compositions | AGO2, EXOSC9, C5 | MCL1 4020/4885CA9 1526/4885CA12 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.